Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion

Vascular Access Devices Clinical Trial

Official title:

A Multicenter, Open-label, Randomised, Clinical Trial to Compare the Efficacy and Safety of Actilyse 2 mg/ 2 ml Versus Saline Solution in Restoring Function of an Occluded Central Venous Access Device

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01958164
• Other study ID #: 135.323
• Status: Completed
• Phase: Phase 3
• First received: October 1, 2013
• Last updated: April 16, 2015
• Start date: September 2013
• Est. completion date: April 2014

Study information

• Verified date: April 2015
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Russia: Pharmacological Committee, Ministry of Health
• Study type: Interventional

Clinical Trial Summary

This is a multicentre, open-label, randomised, phase III study designed to evaluate the efficacy and safety of Actilyse 2 mg/2 ml in the restoration of function of CVAD

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion criteria:

• Male and female patients between 18 and 80 years, who signed a written informed consent

• Patients with central venous access device occlusion, which occurred within 24-h before randomisation, where central venous access device is indicated for any of the following: fluid maintenance, chemotherapy, intravenous feeding, haemodialysis, long-term administration of antibiotics or other medication

• Patients with central venous access device occlusion occurred within 24-h before randomisation. Central venous access device is defined by inability to withdraw at least 3 ml of blood from the central venous access device. If multiple lumens are occluded, investigators are to choose and treat only one lumen for the study.

• Signed and dated written informed consent prior to admission to the study in accordance with good clinical practice and the local legislation. Acceptable level of the following laboratory parameters:

• hemoglobin = 80 g/L;

• total white blood cell count = 2.0 x109/L;

• platelets = 50.0 x109/L;

• fibrinogen =0.5 x lower limit of normal;

• international normalized ratio <2 x upper limit of normal;

• activated partial thromboplastin time <2 x upper limit of normal;

• total protein = 35 g/l;

• alanine transaminase <20 x upper limit of normal;

• aspartate transaminase <20 x upper limit of normal;

• total bilirubin <10 x upper limit of normal;

• creatinine <6 x upper limit of normal;

• glucose > 2.8 mmol/l.

Exclusion criteria:

• Any clinical evidence of mechanical or non-thrombotic occlusion

• High risk for bleeding events

• High risk for embolic complications

• Any condition for which bleeding constitutes a significant hazard or would be particularly difficult to manage

• Administration of any fibrinolytic agent within 48 hours before start of study treatment

• Patients who have had any of the following within the previous 48 hours before start of study treatment:

• surgery

• obstetrical delivery

• percutaneous biopsy of viscera or deep tissues

• puncture of non-compressible vessels

• active internal bleeding

• Patients who have thrombocytopenia, other hemostatic defects (including those secondary to severe hepatic or renal disease).

• Pregnancy and lactation.

• Previously known positive results from infectious serology for Human Immunodeficiency Virus (HIV) or hepatitis B surface antigen (HBsAg), or hepatitis C virus.

• Known hypersensitivity to alteplase or gentamicin, or any excipient of Actilyse - Body weight <30 kg.

• Administration of any fibrinolytic agent within 48 hours before start of study treatment.

• Participation in another investigational trial within 30 days prior to the Screening Visit.

• Concomitant treatment with angiotensin-converting-enzyme inhibitors.

• Impossibility to infuse fluids at the volume necessary to infuse study drug (2 ml) into the central venous access device.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Catheter Obstruction
• Vascular Access Devices

Intervention

Drug:
• Actilyse
Actilyse 2mg/2ml will be given if the CVAD has not been restored at time 120min.
• Saline solution
Instil Saline solution 2 ml into the disfunctional CVAD once at time O only for patients enrolled in Group II
• Actilyse
Instil Actilyse 2 mg/ 2 ml into the dysfunctional CVAD at time O.
• Actilyse
Second dose of Actilyse 2mg/2ml will be given if CVAD has not been restored at time 120min.

Locations

Country	Name	City	State
Russian Federation	135.323.1 Boehringer Ingelheim Investigational Site	Akhangelsk
Russian Federation	135.323.2 Boehringer Ingelheim Investigational Site	Krasnodar
Russian Federation	135.323.3 Boehringer Ingelheim Investigational Site	Krasnoyarsk
Russian Federation	135.323.5 Boehringer Ingelheim Investigational Site	Samara
Russian Federation	135.323.7 Boehringer Ingelheim Investigational Site	St. Petersburg

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Patients With Restored CVAD Function at 120 Min After Administration of the First Dose of Study Medication	Proportion (percentage) of patients with restored central venous access device (CVAD) function at 120 min after administration of the first dose of study medication (i.e. Actilyse® or saline solution).	120 minutes after first drug administration	No
Secondary	Restored CVAD Function 30 Minutes After Administration of Study Medication at Time 0	Percentage of patients with restored CVAD function 30 minutes after administration of study medication at time 0 (i.e. Actilyse® or saline solution)	30 minutes after first drug administration	No
Secondary	Restored CVAD Function 30 Minutes After Administration of the Second Dose of Study Medication Actilyse	Percentage of patients with restored CVAD function 30 minutes after administration of the second dose of study medication Actilyse (150 minutes after time 0)	150 minutes after first drug administration	No
Secondary	Restored CVAD Function 120 Minutes After Administration of the Second Dose of Study Medication Actilyse	Percentage of patients with restored CVAD function 120 minutes after administration of the second dose of study medication Actilyse (240 minutes after time 0)	240 minutes after first drug administration	No
Secondary	Percentage of Participants Who Achieved Restored CVAD Function After 1 Dose and 2 Doses, in Patients From the Actilyse Treatment Group.	This endpoint was defined as the number of doses required to achieve restored CVAD function in patients from the actilyse treatment group but was analysed as the percentage of participants who achieved restored CVAD function after 1 dose and 2 doses, in patients from the actilyse treatment group.	0 minutes and 240 minutes	No

External Links

•   Link